Meg Jardine's Publications

• Calciphylaxis Episodes in the Australia and New Zealand Dialysis and Transplant Registry

  Journal articles

  2024

  Kidney International Reports

• Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points

  Journal articles

  2024

  Clinical Journal of the American Society of Nephrology

• Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data

  Journal articles

  2024

  The Lancet Regional Health - Western Pacific

• The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

  Journal articles

  2024

  Kidney International Reports

• Are Observational Reports on the Association of Dialysate Sodium with Mortality Enough to Change Practice? Perspective from the RESOLVE Study Team

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

  Journal articles

  2024

  Kidney International Reports

• Effect of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy

  Journal articles

  2024

  Kidney International Reports

• Adaptive Designs for Clinical Trials in Nephrology

  Journal articles

  2024

  Journal of the American Society of Nephrology

• The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system

  Journal articles

  2024

  Peritoneal Dialysis International

• Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research

  Journal articles

  2024

  Canadian Journal of Kidney Health and Disease

• Alternative klinische Studiendesigns fr die Nephrologieforschung

  Book Chapters

  2024

  Innovationen in der Nephrologie

• Effect of RAAS Inhibitors in People with COVID-19: An Independent Participant Data Meta-Analysis

  Journal articles

  2024

  Journal of the American Society of Nephrology

• ALIGN Subgroup Analyses: Clinically Meaningful Urinary Protein-to-Creatinine Ratio Reductions across Subgroups

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Prognostic Enrichment Using the Klinrisk Model: Insights from Landmark Kidney Disease Clinical Trials

  Journal articles

  2024

  Journal of the American Society of Nephrology

• The Acute Kidney Function Change with Fenofibrate Is Not Damaging: A Post Hoc Analysis of the FIELD Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Performance of eGFR Slope as a Surrogate End Point for Clinical Kidney Events in a Nonglomerular Mechanism of Acute eGFR Change

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Cardiovascular, Kidney, and Safety Outcomes with Canagliflozin in Older Adults: A Pooled Secondary Analysis of the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status

  Journal articles

  2024

  Journal of the American Society of Nephrology

• WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

  Journal articles

  2024

  Kidney International Reports

• Effect of SGLT2 Inhibitors on Discontinuation of Reninangiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

  Journal articles

  2023

  Journal of the American Society of Nephrology

• Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial

  Journal articles

  2023

  Cardiovascular Diabetology

• Cystatin Cbased estimated glomerular filtration rate and risk of stroke in the general population: a prospective cohort study

  Journal articles

  2023

  Clinical Kidney Journal

• Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

  Journal articles

  2023

  Kidney International

• Duration and effectiveness of glucose-lowering regimens in the real world management of diabetes: Data from the Australian EXTEND45 Linked Cohort Study

  Journal articles

  2023

  Endocrine and Metabolic Science